US2014073046A1PendingUtilityA1

Cell Populations Which Co-Express CD49C and CD90

56
Assignee: GARNET BIOTHERAPEUTICS INCPriority: Sep 21, 2001Filed: Mar 11, 2013Published: Mar 13, 2014
Est. expirySep 21, 2021(expired)· nominal 20-yr term from priority
A61P 9/10A61P 43/00A61P 35/00A61P 9/04A61P 5/00A61P 9/00A61P 25/28A61P 25/16A61P 25/00A61P 25/02A61P 19/08C12N 5/0669C12N 2500/32A61K 2035/124A61P 21/00C12N 2506/1353C12N 2500/02C12N 5/0663C12N 5/0623A61P 21/04C12N 5/0673
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and formulate pharmaceutical compositions.

Claims

exact text as granted — not AI-modified
1 . A substantially homogenous cell population which co-express CD49c, CD90 and telomerase. 
     
     
         2 - 96 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.